{"componentChunkName":"component---src-templates-chapter-level-2-chapter-level-2-tsx","path":"/topics/diabetes-type-2/prescribing-information/metformin/","result":{"pageContext":{"chapter":{"id":"74d00fac-f86f-57ad-babf-5d1fe1f9de16","slug":"metformin","fullItemName":"Metformin","depth":2,"htmlHeader":"<!-- begin field 9c5bf6c7-39da-4674-b87c-5f2cd7f4ab44 --><h2>Metformin</h2><!-- end field 9c5bf6c7-39da-4674-b87c-5f2cd7f4ab44 -->","summary":"","htmlStringContent":"<!-- begin item b6c9dbd1-111e-46c9-b4cd-ce497699e549 --><!-- end item b6c9dbd1-111e-46c9-b4cd-ce497699e549 -->","topic":{"id":"4cff0b65-d29e-58db-b418-fcdb1897bd57","topicId":"dba8b2b1-8488-45e6-9329-463370bd9023","topicName":"Diabetes - type 2","slug":"diabetes-type-2","lastRevised":"Last revised in January 2021","chapters":[{"id":"ce93e6b6-8912-5b90-9c15-32bad09cd193","fullItemName":"Summary","slug":"summary","subChapters":[]},{"id":"8d3d821c-c56f-5a60-b009-95b1715d5a30","fullItemName":"Have I got the right topic?","slug":"have-i-got-the-right-topic","subChapters":[]},{"id":"fd9d266b-7574-5ae2-bba8-a649a01dc340","fullItemName":"How up-to-date is this topic?","slug":"how-up-to-date-is-this-topic","subChapters":[{"id":"40e53df7-3aa4-576e-b7a9-d85a43c83320","slug":"changes","fullItemName":"Changes"},{"id":"021a3bbf-b397-508a-89fc-9390fc999490","slug":"update","fullItemName":"Update"}]},{"id":"744742d1-ce8a-5be0-a598-932c5de9082e","fullItemName":"Goals and outcome measures","slug":"goals-outcome-measures","subChapters":[{"id":"f5554f3c-df7d-5d47-af73-8cc512e67ed3","slug":"goals","fullItemName":"Goals"},{"id":"411c8c8f-bfdc-52ae-84ef-e0973b0bde2f","slug":"outcome-measures","fullItemName":"Outcome measures"},{"id":"0ae17253-4d38-5085-b166-aed4eb4776c6","slug":"audit-criteria","fullItemName":"Audit criteria"},{"id":"526d37c4-a641-5eef-90a0-fbf8728df4d4","slug":"qof-indicators","fullItemName":"QOF indicators"},{"id":"cd0c8c03-5408-5e58-8e95-67848862b20a","slug":"qipp-options-for-local-implementation","fullItemName":"QIPP - Options for local implementation"},{"id":"16103129-20c2-589f-ab7b-287ae3cd6db8","slug":"nice-quality-standards","fullItemName":"NICE quality standards"}]},{"id":"52c6d376-183c-509a-b866-5f284378ada4","fullItemName":"Background information","slug":"background-information","subChapters":[{"id":"3df9be9e-2813-553a-9fba-c83b602b3519","slug":"definition","fullItemName":"Definition"},{"id":"992e9977-3edc-5908-9b93-3ccffb16d1bd","slug":"causes","fullItemName":"Causes"},{"id":"823e084d-d878-50ad-9ccc-21b5b2618273","slug":"risk-factors","fullItemName":"Risk factors"},{"id":"e49f375e-b244-5536-9644-f50117e573cd","slug":"prevalence","fullItemName":"Prevalence"},{"id":"9e28b175-c383-51dd-b999-d92f5eadac0c","slug":"prognosis","fullItemName":"Prognosis"},{"id":"f7eabf8c-8aab-5cc0-b9f5-c67e6d4992bf","slug":"complications","fullItemName":"Complications"}]},{"id":"c5223482-bcb9-5292-9da9-a311c0a2e2f6","fullItemName":"Diagnosis","slug":"diagnosis","subChapters":[{"id":"324f22c7-6746-5065-a0e5-f536cc9b7b08","slug":"diagnosis-in-adults","fullItemName":"Diagnosis in adults"},{"id":"1a3a574b-4a8b-5631-afa1-71b1e679c80b","slug":"diagnosis-in-children-young-people","fullItemName":"Diagnosis in children and young people"},{"id":"6cd92df9-dfac-50e7-91bf-aa8a84abeb25","slug":"when-to-suspect-hyperglycaemic-emergencies-dka-hhs","fullItemName":"When to suspect hyperglycaemic emergencies (DKA and HHS)"},{"id":"441e294a-e6e2-51e2-a4ff-43c90bd062cb","slug":"when-to-suspect-hypoglycaemia","fullItemName":"When to suspect hypoglycaemia"}]},{"id":"82ac0366-3d17-50b1-aa1e-a3e99d6e5144","fullItemName":"Management","slug":"management","subChapters":[{"id":"08850dc1-fe0b-5c26-a333-c4cb006e5e75","slug":"management-adults","fullItemName":"Scenario: Management - adults"},{"id":"dfab96b2-5e91-57ff-bec0-fa00af42079e","slug":"management-children-young-people","fullItemName":"Scenario: Management - children and young people"}]},{"id":"1b4e6a82-89a8-5319-bf06-05194b98d82d","fullItemName":"Prescribing information","slug":"prescribing-information","subChapters":[{"id":"74d00fac-f86f-57ad-babf-5d1fe1f9de16","slug":"metformin","fullItemName":"Metformin"},{"id":"72616639-7871-5c48-9532-fef54860cf16","slug":"dpp-4-inhibitors","fullItemName":"DPP-4 inhibitors"},{"id":"aa941789-8eb7-560d-8aa9-d295ec1ef445","slug":"pioglitazone","fullItemName":"Pioglitazone"},{"id":"8c669638-5b99-55a8-a887-f814f6b5fcda","slug":"sulfonylureas","fullItemName":"Sulfonylureas"},{"id":"60c24d46-ee19-572f-8edb-6c8825ae2e4c","slug":"sglt-2-inhibitors","fullItemName":"SGLT-2 inhibitors"},{"id":"d1fec183-3ce2-5a1a-8a1f-d311251169ed","slug":"glp-1-receptor-agonists","fullItemName":"GLP-1 receptor agonists"}]},{"id":"b20c2a35-6a9f-553f-a0ae-37ce10a454e1","fullItemName":"Supporting evidence","slug":"supporting-evidence","subChapters":[]},{"id":"02f494c5-26fc-568d-b011-fa06912e1b30","fullItemName":"How this topic was developed","slug":"how-this-topic-was-developed","subChapters":[{"id":"a679ba5d-d00a-5885-93d4-254752ecc2be","slug":"search-strategy","fullItemName":"Search strategy"},{"id":"73ffe0ed-8b83-5a6a-b466-3413fb4d962e","slug":"stakeholder-engagement","fullItemName":"Stakeholder engagement"},{"id":"1e48f1e8-8da5-5805-808b-c23b6b74a24d","slug":"evidence-exclusion-criteria","fullItemName":"Evidence exclusion criteria"},{"id":"12814e2d-5205-5714-a20b-3a35be729f4e","slug":"organizational-behavioural-financial-barriers","fullItemName":"Organizational, behavioural and financial barriers"},{"id":"16bc4fdb-b9af-5017-abab-b2da6db4889c","slug":"declarations-of-interest","fullItemName":"Declarations of interest"}]},{"id":"e694c0d9-6d5f-5969-82fa-6f4dcfb5baf7","fullItemName":"References","slug":"references","subChapters":[]}]},"parentChapter":{"id":"1b4e6a82-89a8-5319-bf06-05194b98d82d","slug":"prescribing-information","fullItemName":"Prescribing information"},"subChapters":[{"id":"05ad8881-ab27-580a-a8d6-064eeb8aa633","slug":"recommended-doses","fullItemName":"Recommended doses","depth":3,"htmlHeader":"<!-- begin field 09c32f93-3d17-46b1-a302-f7da97e80e79 --><h3>Recommended doses</h3><!-- end field 09c32f93-3d17-46b1-a302-f7da97e80e79 -->","summary":"","htmlStringContent":"<!-- begin item 007fa234-ae3e-4a79-9af2-1b7875a6ffc3 --><!-- begin field 51c39a91-8914-4b1d-8615-95691410976d --><p><strong>Metformin is currently the only available biguanide.</strong></p><ul><li>For standard-release metformin tablets:<ul><li>500 mg with breakfast for at least 1 week, <em>then </em>500 mg with breakfast and evening meal for at least 1 week, <em>then </em>500 mg with breakfast, lunch, and evening meal thereafter; maximum dose 2 g daily (in divided doses).</li></ul></li><li>For modified-release metformin tablets:<ul><li>Initially 500 mg once daily, then increased if necessary up to 2 g once daily, dose increased gradually, every 10–15 days, dose to be taken with evening meal.</li><li>Alternatively, dose increased to 1 g twice daily, dose to be taken with meals, alternative dose only to be used if control not achieved with once daily dose regimen. If control is still not achieved, then change to standard-release tablets.</li></ul></li></ul><p> [<a class=\"bibliography-reference internal-reference\" href=\"/topics/diabetes-type-2/references/\">Joint Formulary Committee, 2020</a>]</p><!-- end field 51c39a91-8914-4b1d-8615-95691410976d --><!-- end item 007fa234-ae3e-4a79-9af2-1b7875a6ffc3 -->","subChapters":[]},{"id":"5d27da8d-575c-53b7-b61b-354f40dbc006","slug":"initiating-monitoring","fullItemName":"Initiating and monitoring","depth":3,"htmlHeader":"<!-- begin field 3334d7d5-92dc-4eda-b4d4-118bc5651673 --><h3>Initiating and monitoring</h3><!-- end field 3334d7d5-92dc-4eda-b4d4-118bc5651673 -->","summary":"","htmlStringContent":"<!-- begin item 1ee357f9-4f6c-4dc2-8b56-5b3c825d1c93 --><!-- begin field a556ce02-5be1-4d55-b021-0448b2c895b4 --><ul><li><strong>Before starting treatment with metformin, check renal function.</strong><ul><li>Do not start metformin treatment if estimated glomerular filtration rate (eGFR) is less than 30 mL/min/1.73 m<sup>2</sup>.</li></ul></li><li><strong>During treatment with metformin monitor renal function:</strong><ul><li>At least once a year in people with normal renal function.</li><li>At least twice a year in people with additional risk factors for renal impairment, such as the elderly, or if deterioration in renal function is suspected.</li><li>Review the dose of metformin if eGFR is less than 45 mL/min/1.73 m<sup>2</sup>.</li></ul></li><li><strong>Stop treatment with metformin:</strong><ul><li>If eGFR is less than 30 mL/min/1.73 m<sup>2</sup>.</li><li>In people at risk of tissue hypoxia or sudden deterioration in renal function.</li></ul></li></ul><p>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/diabetes-type-2/references/\">ABPI, 2020</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/diabetes-type-2/references/\">Joint Formulary Committee, 2020</a>]</p><!-- end field a556ce02-5be1-4d55-b021-0448b2c895b4 --><!-- end item 1ee357f9-4f6c-4dc2-8b56-5b3c825d1c93 -->","subChapters":[]},{"id":"e0fa8866-8948-5cb8-a7a8-bfda70981672","slug":"contraindications-cautions","fullItemName":"Contraindications and cautions","depth":3,"htmlHeader":"<!-- begin field 0dcb7bfe-11b6-4af5-a013-5135804fbe58 --><h3>Contraindications and cautions</h3><!-- end field 0dcb7bfe-11b6-4af5-a013-5135804fbe58 -->","summary":"","htmlStringContent":"<!-- begin item 49d1fd72-7567-467d-b9ec-2d826296eacd --><!-- begin field 65a7d263-b976-4efe-b059-7405935e0efa --><ul><li><strong>Do not prescribe metformin to people:</strong><ul><li>At risk of <a class=\"topic-reference internal-reference\" href=\"/topics/diabetes-type-2/prescribing-information/metformin/#adverse-effects\">lactic acidosis</a>, including people with:<ul><li>Diabetic ketoacidosis.</li><li>Estimated glomerular filtration rate (eGFR) less than 30 mL/minute/1.73 m<sup>2</sup> (for standard release) or less than 45 mL/minute/1.73 m<sup>2</sup> (for modified release).</li><li>Risk of acute kidney injury, such as dehydration, prolonged fasting, severe infection, or shock.</li><li>Conditions that may cause tissue hypoxia, such as cardiac or respiratory failure, recent myocardial infarction, or shock.</li><li>Hepatic insufficiency, acute alcohol intoxication.</li></ul></li></ul></li><li><strong>Prescribe metformin with caution to people with:</strong><ul><li>Potential impaired renal function, for example use of concomitant nephrotoxic drugs, or in elderly people (due to the increased risk of lactic acidosis).</li></ul></li></ul><p>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/diabetes-type-2/references/\">ABPI, 2020</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/diabetes-type-2/references/\">Joint Formulary Committee, 2020</a>]</p><!-- end field 65a7d263-b976-4efe-b059-7405935e0efa --><!-- end item 49d1fd72-7567-467d-b9ec-2d826296eacd -->","subChapters":[]},{"id":"57b4eea6-84f7-526e-9c6f-c13a73c5e750","slug":"adverse-effects","fullItemName":"Adverse effects","depth":3,"htmlHeader":"<!-- begin field 3eec9806-4311-4ce5-a6d1-e918d16f04d8 --><h3>Adverse effects</h3><!-- end field 3eec9806-4311-4ce5-a6d1-e918d16f04d8 -->","summary":"","htmlStringContent":"<!-- begin item 0c6fbb84-4541-49a0-b8c7-d07bbb0bffde --><!-- begin field f2485bb0-5962-4f69-853f-65f3dc6bbec4 --><ul><li><strong>Adverse effects of metformin include:</strong><ul><li>Gastrointestinal — nausea, vomiting, diarrhoea, abdominal pain, loss of appetite, taste disturbance. These are common, occur most frequently during initiation of treatment, and resolve spontaneously in most cases. </li><li>Lactic acidosis — this is rare but potentially life-threatening.<ul><li>It has an insidious onset with non-specific signs and symptoms, such as abdominal pain, anorexia, hypothermia, lethargy, nausea, respiratory distress, and vomiting.</li><li>Stop metformin treatment if estimated glomerular filtration rate (eGFR) is less than 30 mL/min/1.73 m<sup>2</sup>.</li></ul></li><li>Vitamin B12 deficiency — reduced vitamin B12 absorption has been reported during long-term use. See the CKS topic on <a class=\"topic-reference external-reference\" href=\"/topics/anaemia-b12-folate-deficiency/\">Anaemia - B12 and folate deficiency</a> for more information.</li><li>Skin reactions including erythema, pruritus, and urticaria (rare). </li></ul></li></ul><p> [<a class=\"bibliography-reference internal-reference\" href=\"/topics/diabetes-type-2/references/\">Joint Formulary Committee, 2020</a>]</p><!-- end field f2485bb0-5962-4f69-853f-65f3dc6bbec4 --><!-- end item 0c6fbb84-4541-49a0-b8c7-d07bbb0bffde -->","subChapters":[]},{"id":"c4b5976e-164d-5b62-999f-a7ca95eec934","slug":"drug-interactions","fullItemName":"Drug interactions","depth":3,"htmlHeader":"<!-- begin field 383bedbb-0df2-4b85-a159-bc03538cd039 --><h3>Drug interactions</h3><!-- end field 383bedbb-0df2-4b85-a159-bc03538cd039 -->","summary":"","htmlStringContent":"<!-- begin item 7dfddf87-2157-4830-87e8-f2df2d79d248 --><!-- begin field 4e4c45f3-e290-400c-91df-d0fdfe0d3d44 --><ul><li><strong>Drug interactions associated with metformin include:</strong><ul><li>Alcohol — increased risk of <a class=\"topic-reference internal-reference\" href=\"/topics/diabetes-type-2/prescribing-information/metformin/#adverse-effects\">lactic acidosis</a>. In addition, the hypoglycaemic effect of metformin may be enhanced by alcohol. Concurrent use is not recommended.</li><li>Beta-blockers — the warning signs of hypoglycaemia (such as tremor) may be masked during concurrent treatment.</li><li>Ketotifen — platelet count may be depressed when metformin is given with ketotifen. Avoid concurrent use. </li><li>Topiramate — plasma concentration of metformin may be increased by topiramate.</li><li>Other antidiabetic drugs — caution is advised when metformin is used in combination (due to the risk of hypoglycaemia).</li></ul></li><li><strong>In addition:</strong><ul><li><strong>The blood glucose-lowering effects of metformin may be enhanced by:</strong><ul><li>Angiotensin-converting enzyme (ACE) inhibitors.</li><li>Anabolic steroids.</li><li>Monoamine oxidase inhibitors (MAOIs).</li><li>Testosterone.</li></ul></li><li><strong>The blood glucose-lowering effects of metformin </strong><strong>may be antagonized by:</strong><ul><li>Corticosteroids.</li><li>Diuretics (thiazide and related, and loop). </li><li>Oestrogens and progestogens.</li></ul></li><li><strong>Metformin is a substrate of both organic cation transporters, OCT1 and OCT2. Co-administration of metformin with:</strong><ul><li>Inhibitors of OCT1 (such as verapamil) may reduce efficacy of metformin.</li><li>Inducers of OCT1 (such as rifampicin) may increase gastrointestinal absorption and efficacy of metformin.</li><li>Inhibitors of OCT2 (such as cimetidine, dolutegravir, ranolazine, trimethoprim, vandetanib, isavuconazole) may decrease the renal elimination of metformin and thus lead to an increase in metformin plasma concentration.</li><li>Inhibitors of both OCT1 and OCT2 (such as crizotinib, olaparib) may alter efficacy and renal elimination of metformin.</li></ul></li><li>Caution is therefore advised, especially in patients with renal impairment, when these drugs are co-administered with metformin, as metformin plasma concentration may increase. If needed, dose adjustment of metformin may be considered as OCT inhibitors/inducers may alter the efficacy of metformin.</li></ul></li></ul><p>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/diabetes-type-2/references/\">ABPI, 2020</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/diabetes-type-2/references/\">Joint Formulary Committee, 2020</a>]</p><!-- end field 4e4c45f3-e290-400c-91df-d0fdfe0d3d44 --><!-- end item 7dfddf87-2157-4830-87e8-f2df2d79d248 -->","subChapters":[]}]}}},"staticQueryHashes":["3666801979"]}